USP Releases Compounding Compendium

News
Article

USP releases compendium of quality standards for compounded medicines.

The United States Pharmacopeia Convention (USP) has published the USP Compounding Compendium to provide easy access to quality related standards for compounded medicines. The compendium gives compounding practitioners access to all compounding-related general chapters from the United States Pharmacopeia–National Formulary (USP–NF) and features more than 40 supporting general chapters and more than 170 compounding preparation monographs. It also includes the USP–NF General Notices and Requirements, “which provide definitions and important information necessary to correctly interpret and apply compounding standards.”

“USP has a deep historic connection to the practice of pharmacy, stretching back to the very beginning of our origination nearly 200 years ago when practitioners regularly prepared medicines as-needed,” noted USP Chief Executive Officer Ronald T. Piervincenzi, PhD, in a press release. “Our founders, most of whom practiced and taught medicine and/or pharmacy, promoted quality standards as a tool to advance their profession and improve public health, and USP’s commitment to those core ideals continues today.”

The USP Compounding Compendium will be updated with the release of each new USP–NF edition and supplement. Subscribers can access and download all updates during their 12-month subscription period. USP has partnered with the International Academy of Compounding Pharmacists (IACP) and the National Community Pharmacy Association (NCPA) to enable their members to purchase the USP Compounding Compendium directly through the IACP and NCPA websites.

Source: USP.org

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.